NCT00811694

Brief Summary

A variety of studies demonstrate that ocular blood flow is altered in glaucoma. Various animal and human studies have shown an increase in retinal and optic nerve head blood flow in response to diffuse luminance flicker. Based on studies with ERG, this effect has been attributed to augmented activity in the retinal ganglion cells and associated axons indicating a coupling mechanism between neuronal activity and retinal blood flow. Whereas a variety of studies have confirmed these effects, the knowledge about this coupling in the retina of patients with glaucoma is sparse. Recently the investigators could show that flicker induced vasodilatation is blunted in patients with open angle glaucoma. However, the investigators results are limited by the fact that only data about retinal vessel diameters, not blood flow per se, are available. The further development of the investigators current flicker stimulation technique now allows us to determine blood flow velocity during flicker stimulation. Thus, in the current study, the investigators set out to determine whether this blood flow response is impaired in patients with glaucoma as compared to those in healthy volunteers and whether this is related to altered neural activity. The study objective was, to investigate whether the blood flow response to flicker stimulation is altered in patients with glaucoma.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
15

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Oct 2006

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2006

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2007

Completed
1.3 years until next milestone

First Submitted

Initial submission to the registry

July 2, 2008

Completed
6 months until next milestone

First Posted

Study publicly available on registry

December 19, 2008

Completed
3.4 years until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2012

Completed
Last Updated

November 21, 2014

Status Verified

November 1, 2014

Enrollment Period

6 months

First QC Date

July 2, 2008

Last Update Submit

November 20, 2014

Conditions

Keywords

glaucomaficker stimulationocular blood flow

Outcome Measures

Primary Outcomes (4)

  • Retinal blood velocity (laser Doppler velocimetry)

    measurements done only once on the studyday

  • Retinal arterial and venous diameter (Retinal vessel analyzer)

    measurements done only once on the studyday

  • Optic nerve head blood flow (laser Doppler flowmetry)

    measurements done only once on the studyday

  • Latency and amplitude (pattern ERG)

    measurements done only once on the studyday

Secondary Outcomes (1)

  • Mean arterial pressure

    measurements done only once on the studyday

Study Arms (2)

a

15 male and 15 female patients with glaucoma

Other: ocular blood flow measurements

b

30 sex matched healthy volunteers

Other: ocular blood flow measurements

Interventions

non-invasive haemodynamic measurements of retinal vessel diameters, laser Doppler flowmetry and laser Doppler velocimetry

ab

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Men and women aged between 20 and 80 years.
  • Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant.
  • Men and women will be included in equal parts. A pregnancy test will be performed at screening.
  • Ametropia of less than 3 diopters and anisometropia of less than 1 diopter.

You may not qualify if:

  • Treatment with vasoactive drugs.
  • Presence of intraocular pathology other than open angle glaucoma.
  • Presence of ocular hypertension or PEX (pseudoexfoliation) glaucoma
  • History or family history of epilepsy.
  • Pregnancy.
  • Diabetes mellitus.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Clinical Pharmacology, Meical University of Vienna, Austria

Vienna, 1090, Austria

Location

MeSH Terms

Conditions

Glaucoma

Condition Hierarchy (Ancestors)

Ocular HypertensionEye Diseases

Study Officials

  • Gabriele Fuchsjäger Mayrl, MD

    Department of Clinical Pharmacology, Meical University of Vienna

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Sponsor Type
OTHER

Study Record Dates

First Submitted

July 2, 2008

First Posted

December 19, 2008

Study Start

October 1, 2006

Primary Completion

April 1, 2007

Study Completion

May 1, 2012

Last Updated

November 21, 2014

Record last verified: 2014-11

Locations